{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T04:22:14Z","timestamp":1794716534493,"version":"4.9.1"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007547","name":"Fourth Military Medical University","doi-asserted-by":"publisher","award":["2022ZZXM044,"],"award-info":[{"award-number":["2022ZZXM044,"]}],"id":[{"id":"10.13039\/501100007547","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007547","name":"Fourth Military Medical University","doi-asserted-by":"publisher","award":["2025KXKT115"],"award-info":[{"award-number":["2025KXKT115"]}],"id":[{"id":"10.13039\/501100007547","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Key Research and Development Program of China Key Research and Development Project of Shaanxi Province"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Old World\n                    <jats:italic>orthohantaviruses<\/jats:italic>\n                    , including Hantaan virus (HTNV), cause hemorrhagic fever with renal syndrome (HFRS) in Eurasia. Available inactivated vaccines often induce low neutralizing antibodies and short-term protection. We evaluated nucleic acid vaccines expressing a prefusion-stabilized HTNV glycoprotein in female BALB\/c mice. Both DNA and mRNA-LNP versions elicited robust neutralizing antibodies by strongly activating germinal centers, which protected mice against high-dose HTNV challenge. We further tested heterologous prime-boost regimens, where mice primed with inactivated vaccine received different boosters. All boosters increased neutralizing titers, but only the prefusion-stabilized glycoprotein mRNA-LNP vaccine raised titers to the level achieved by its own full primary vaccination course. This demonstrates the immunogen\u2019s superiority in developing next-generation vaccines and its unique ability to potently recall memory B cells induced by suboptimal inactivated vaccines. Thus, prefusion-stabilized glycoprotein-based nucleic acid vaccines are promising candidates for advanced\n                    <jats:italic>orthohantavirus<\/jats:italic>\n                    vaccine development.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-70285-7","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T16:53:12Z","timestamp":1773507192000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Prefusion-stabilized Hantaan virus glycoprotein nucleic acid vaccine elicits potent neutralizing antibody responses via germinal center activation"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3980-8547","authenticated-orcid":false,"given":"Wei","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamei","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5688-9589","authenticated-orcid":false,"given":"Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiqi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0698-4744","authenticated-orcid":false,"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6963-2757","authenticated-orcid":false,"given":"Chuantao","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4309-6395","authenticated-orcid":false,"given":"Jing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemin","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongshen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linfeng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangchao","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1482-6124","authenticated-orcid":false,"given":"Yingfeng","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8893-8444","authenticated-orcid":false,"given":"Zhikai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2039-509X","authenticated-orcid":false,"given":"Fanglin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,14]]},"reference":[{"key":"70285_CR1","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.3390\/v13081561","volume":"13","author":"K Meier","year":"2021","unstructured":"Meier, K., Thorkelsson, S. R., Quemin, E. R. J. & Rosenthal, M. Hantavirus replication cycle-an updated structural virology perspective. Viruses-Basel 13, 1561 (2021).","journal-title":"Viruses-Basel"},{"key":"70285_CR2","doi-asserted-by":"publisher","first-page":"e371","DOI":"10.1016\/S1473-3099(23)00128-7","volume":"23","author":"PA Vial","year":"2023","unstructured":"Vial, P. A. et al. Hantavirus in humans: a review of clinical aspects and management. Lancet Infect. Dis. 23, e371\u2013e382 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"70285_CR3","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nrmicro3066","volume":"11","author":"A Vaheri","year":"2013","unstructured":"Vaheri, A. et al. Uncovering the mysteries of hantavirus infections. Nat. Rev. Microbiol. 11, 539\u2013550 (2013).","journal-title":"Nat. Rev. Microbiol."},{"key":"70285_CR4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s12250-016-3899-x","volume":"32","author":"H Jiang","year":"2017","unstructured":"Jiang, H. et al. Hantavirus infection: a global zoonotic challenge. Virol. Sin. 32, 32\u201343 (2017).","journal-title":"Virol. Sin."},{"key":"70285_CR5","doi-asserted-by":"crossref","unstructured":"Deng X., Xie Y., Du S. Distinct genotype of hantavirus infection in rodents in jiangxi province, China, in 2020\u20132021. Zoonoses 2 (2022),","DOI":"10.15212\/ZOONOSES-2022-0034"},{"key":"70285_CR6","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/zph.12175","volume":"62","author":"J Roda Gracia","year":"2015","unstructured":"Roda Gracia, J., Schumann, B. & Seidler, A. Climate variability and the occurrence of human puumala hantavirus infections in Europe: a systematic review. Zoonoses public health 62, 465\u2013478 (2015).","journal-title":"Zoonoses public health"},{"key":"70285_CR7","doi-asserted-by":"crossref","unstructured":"Douglas K. O., Payne K., Sabino-Santos G. Jr., Agard J. Influence of climatic factors on human hantavirus infections in Latin America and the Caribbean: a Systematic Review. 11 (Pathogens Basel, Switzerland, 2021),","DOI":"10.3390\/pathogens11010015"},{"key":"70285_CR8","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1159\/000067925","volume":"45","author":"HW Cho","year":"2002","unstructured":"Cho, H. W., Howard, C. R. & Lee, H. W. Review of an inactivated vaccine against hantaviruses. Intervirology 45, 328\u2013333 (2002).","journal-title":"Intervirology"},{"key":"70285_CR9","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1006\/viro.2001.1171","volume":"289","author":"C L\u00f6ber","year":"2001","unstructured":"L\u00f6ber, C., Anheier, B., Lindow, S., Klenk, H. & Feldmann, H. The Hantaan virus glycoprotein precursor is cleaved at the conserved pentapeptide WAASA. Virology 289, 224\u2013229 (2001).","journal-title":"Virology"},{"key":"70285_CR10","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1099\/vir.0.81083-0","volume":"86","author":"ND Tischler","year":"2005","unstructured":"Tischler, N. D., Gonzalez, A., Perez-Acle, T., Rosemblatt, M. & Valenzuela, P. D. Hantavirus Gc glycoprotein: evidence for a class II fusion protein. J. Gen. Virol. 86, 2937\u20132947 (2005).","journal-title":"J. Gen. Virol."},{"key":"70285_CR11","doi-asserted-by":"publisher","first-page":"e1005813","DOI":"10.1371\/journal.ppat.1005813","volume":"12","author":"P Guardado-Calvo","year":"2016","unstructured":"Guardado-Calvo, P. et al. Mechanistic insight into bunyavirus-induced membrane fusion from structure-function analyses of the hantavirus envelope glycoprotein Gc. PLoS Pathog. 12, e1005813 (2016).","journal-title":"PLoS Pathog."},{"key":"70285_CR12","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cell.2020.08.023","volume":"183","author":"A Serris","year":"2020","unstructured":"Serris, A. et al. The hantavirus surface glycoprotein lattice and its fusion control mechanism. Cell 183, 442\u2013456.e416 (2020).","journal-title":"Cell"},{"key":"70285_CR13","doi-asserted-by":"publisher","first-page":"e46028","DOI":"10.7554\/eLife.46028","volume":"8","author":"EA Bignon","year":"2019","unstructured":"Bignon, E. A., Albornoz, A., Guardado-Calvo, P., Rey, F. A. & Tischler, N. D. Molecular organization and dynamics of the fusion protein Gc at the hantavirus surface. eLife 8, e46028 (2019).","journal-title":"eLife"},{"key":"70285_CR14","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.3390\/v6041801","volume":"6","author":"N Cifuentes-Munoz","year":"2014","unstructured":"Cifuentes-Munoz, N., Salazar-Quiroz, N. & Tischler, N. D. Hantavirus Gn and Gc envelope glycoproteins: key structural units for virus cell entry and virus assembly. Viruses 6, 1801\u20131822 (2014).","journal-title":"Viruses"},{"key":"70285_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/infdis\/jiad235","volume":"229","author":"GC Paulsen","year":"2023","unstructured":"Paulsen, G. C. et al. Safety and immunogenicity of an Andes virus DNA vaccine by needle-free injection: a randomized, controlled phase 1 study. J. Infect. Dis. 229, 30\u201338 (2023).","journal-title":"J. Infect. Dis."},{"key":"70285_CR16","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.1016\/j.vaccine.2013.07.025","volume":"31","author":"JW Hooper","year":"2013","unstructured":"Hooper, J. W., Josleyn, M., Ballantyne, J. & Brocato, R. A novel Sin Nombre virus DNA vaccine and its inclusion in a candidate pan-hantavirus vaccine against hantavirus pulmonary syndrome (HPS) and hemorrhagic fever with renal syndrome (HFRS). Vaccine 31, 4314\u20134321 (2013).","journal-title":"Vaccine"},{"key":"70285_CR17","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.virol.2005.11.035","volume":"347","author":"JW Hooper","year":"2006","unstructured":"Hooper, J. W., Custer, D. M., Smith, J. & Wahl-Jensen, V. Hantaan\/Andes virus DNA vaccine elicits a broadly cross-reactive neutralizing antibody response in nonhuman primates. Virology 347, 208\u2013216 (2006).","journal-title":"Virology"},{"key":"70285_CR18","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1016\/j.vaccine.2015.05.007","volume":"33","author":"DB Jiang","year":"2015","unstructured":"Jiang, D. B. et al. Construction and evaluation of a DNA vaccine encoding Hantavirus glycoprotein N-terminal fused with lysosome-associated membrane protein. Vaccine 33, 3367\u20133376 (2015).","journal-title":"Vaccine"},{"key":"70285_CR19","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.antiviral.2017.12.011","volume":"150","author":"DB Jiang","year":"2018","unstructured":"Jiang, D. B. et al. Hantavirus Gc induces long-term immune protection via LAMP-targeting DNA vaccine strategy. Antivir. Res. 150, 174\u2013182 (2018).","journal-title":"Antivir. Res."},{"key":"70285_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2023.199149","volume":"334","author":"R Liu","year":"2023","unstructured":"Liu, R. et al. Investigation of a subunit protein vaccine for HFRS based on a consensus sequence between envelope glycoproteins of HTNV and SEOV. Virus Res. 334, 199149 (2023).","journal-title":"Virus Res."},{"key":"70285_CR21","doi-asserted-by":"publisher","first-page":"e1005948","DOI":"10.1371\/journal.ppat.1005948","volume":"12","author":"S Willensky","year":"2016","unstructured":"Willensky, S. et al. Crystal structure of glycoprotein C from a hantavirus in the post-fusion conformation. PLoS Pathog. 12, e1005948 (2016).","journal-title":"PLoS Pathog."},{"key":"70285_CR22","doi-asserted-by":"publisher","first-page":"e00378","DOI":"10.1128\/JVI.00378-17","volume":"91","author":"I Rissanen","year":"2017","unstructured":"Rissanen, I. et al. Structural transitions of the conserved and metastable hantaviral glycoprotein envelope. J. Virol. 91, e00378\u2013e00417 (2017).","journal-title":"J. Virol."},{"key":"70285_CR23","doi-asserted-by":"publisher","first-page":"e58242","DOI":"10.7554\/eLife.58242","volume":"9","author":"I Rissanen","year":"2020","unstructured":"Rissanen, I. et al. Molecular rationale for antibody-mediated targeting of the hantavirus fusion glycoprotein. eLife 9, e58242 (2020).","journal-title":"eLife"},{"key":"70285_CR24","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02531-20","volume":"12","author":"I Rissanen","year":"2021","unstructured":"Rissanen, I. et al. Structural basis for a neutralizing antibody response elicited by a recombinant hantaan virus Gn immunogen. mBio 12, e0253120 (2021).","journal-title":"mBio"},{"key":"70285_CR25","doi-asserted-by":"publisher","first-page":"e00028","DOI":"10.1128\/mBio.00028-20","volume":"11","author":"J Duehr","year":"2020","unstructured":"Duehr, J. et al. Neutralizing monoclonal antibodies against the Gn and the Gc of the andes virus glycoprotein spike complex protect from virus challenge in a preclinical hamster model. mBio 11, e00028\u2013e00120 (2020).","journal-title":"mBio"},{"key":"70285_CR26","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1038\/s41564-023-01413-y","volume":"8","author":"R Stass","year":"2023","unstructured":"Stass, R. et al. Mechanistic basis for potent neutralization of Sin Nombre hantavirus by a human monoclonal antibody. Nat. Microbiol. 8, 1293\u20131303 (2023).","journal-title":"Nat. Microbiol."},{"key":"70285_CR27","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adg1855","volume":"15","author":"E Mittler","year":"2023","unstructured":"Mittler, E. et al. Structural and mechanistic basis of neutralization by a pan-hantavirus protective antibody. Sci. Transl. Med. 15, eadg1855 (2023).","journal-title":"Sci. Transl. Med."},{"key":"70285_CR28","doi-asserted-by":"publisher","first-page":"e81743","DOI":"10.7554\/eLife.81743","volume":"12","author":"TB Engdahl","year":"2023","unstructured":"Engdahl, T. B. et al. Antigenic mapping and functional characterization of human New World hantavirus neutralizing antibodies. eLife 12, e81743 (2023).","journal-title":"eLife"},{"key":"70285_CR29","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1126\/science.1243283","volume":"342","author":"JS McLellan","year":"2013","unstructured":"McLellan, J. S. et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342, 592\u2013598 (2013).","journal-title":"Science"},{"key":"70285_CR30","doi-asserted-by":"publisher","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","volume":"114","author":"J Pallesen","year":"2017","unstructured":"Pallesen, J. et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc. Natl. Acad. Sci. USA 114, E7348\u2013E7357 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"70285_CR31","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1128\/JVI.00481-09","volume":"84","author":"J Hepojoki","year":"2010","unstructured":"Hepojoki, J., Strandin, T., Vaheri, A. & Lankinen, H. Interactions and oligomerization of hantavirus glycoproteins. J. Virol. 84, 227\u2013242 (2010).","journal-title":"J. Virol."},{"key":"70285_CR32","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1007\/s13238-011-1083-5","volume":"2","author":"Z Li","year":"2011","unstructured":"Li, Z., Zhang, Y. & Sun, B. Current understanding of Th2 cell differentiation and function. Protein cell 2, 604\u2013611 (2011).","journal-title":"Protein cell"},{"key":"70285_CR33","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1084\/jem.192.11.1545","volume":"192","author":"D Breitfeld","year":"2000","unstructured":"Breitfeld, D. et al. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J. Exp. Med. 192, 1545\u20131552 (2000).","journal-title":"J. Exp. Med."},{"key":"70285_CR34","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1084\/jem.193.12.1373","volume":"193","author":"CH Kim","year":"2001","unstructured":"Kim, C. H. et al. Subspecialization of CXCR5+ T cells: B helper activity is focused in a germinal center-localized subset of CXCR5+ T cells. J. Exp. Med. 193, 1373\u20131381 (2001).","journal-title":"J. Exp. Med."},{"key":"70285_CR35","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1084\/jem.192.11.1553","volume":"192","author":"P Schaerli","year":"2000","unstructured":"Schaerli, P. et al. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J. Exp. Med. 192, 1553\u20131562 (2000).","journal-title":"J. Exp. Med."},{"key":"70285_CR36","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3109\/23744235.2015.1121289","volume":"48","author":"Y Zheng","year":"2016","unstructured":"Zheng, Y. et al. Long-term persistence of anti-hantavirus antibodies in sera of patients undergoing hemorrhagic fever with renal syndrome and subjects vaccinated against the disease. Infect. Dis. (Lond., Engl.) 48, 262\u2013266 (2016).","journal-title":"Infect. Dis. (Lond., Engl.)"},{"key":"70285_CR37","doi-asserted-by":"publisher","first-page":"8016","DOI":"10.1016\/j.vaccine.2020.10.035","volume":"38","author":"JY Song","year":"2020","unstructured":"Song, J. Y. et al. Immunogenicity and safety of a modified three-dose priming and booster schedule for the Hantaan virus vaccine (Hantavax): a multi-center phase III clinical trial in healthy adults. Vaccine 38, 8016\u20138023 (2020).","journal-title":"Vaccine"},{"key":"70285_CR38","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3389\/fcimb.2016.00185","volume":"6","author":"LF Cheng","year":"2016","unstructured":"Cheng, L. F. et al. Incorporation of GM-CSF or CD40L enhances the immunogenicity of hantaan virus-like particles. Front Cell Infect. Microbiol 6, 185 (2016).","journal-title":"Front Cell Infect. Microbiol"},{"key":"70285_CR39","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/BF01309700","volume":"126","author":"J Arikawa","year":"1992","unstructured":"Arikawa, J., Yao, J. S., Yoshimatsu, K., Takashima, I. & Hashimoto, N. Protective role of antigenic sites on the envelope protein of Hantaan virus defined by monoclonal antibodies. Arch. Virol. 126, 271\u2013281 (1992).","journal-title":"Arch. Virol."},{"key":"70285_CR40","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S0006-291X(02)02491-9","volume":"298","author":"Z Xu","year":"2002","unstructured":"Xu, Z., Wei, L., Wang, L., Wang, H. & Jiang, S. The in vitro and in vivo protective activity of monoclonal antibodies directed against Hantaan virus: potential application for immunotherapy and passive immunization. Biochem.l Biophys. Res. Commun. 298, 552\u2013558 (2002).","journal-title":"Biochem.l Biophys. Res. Commun."},{"key":"70285_CR41","doi-asserted-by":"publisher","first-page":"264ra162","DOI":"10.1126\/scitranslmed.3010082","volume":"6","author":"JW Hooper","year":"2014","unstructured":"Hooper, J. W. et al. DNA vaccine-derived human IgG produced in transchromosomal bovines protects in lethal models of hantavirus pulmonary syndrome. Sci. Transl. Med. 6, 264ra162 (2014).","journal-title":"Sci. Transl. Med."},{"key":"70285_CR42","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3851\/IMP2875","volume":"20","author":"PA Vial","year":"2015","unstructured":"Vial, P. A. et al. A non-randomized multicentre trial of human immune plasma for treatment of hantavirus cardiopulmonary syndrome caused by Andes virus. Antivir. Ther. 20, 377\u2013386 (2015).","journal-title":"Antivir. Ther."},{"key":"70285_CR43","doi-asserted-by":"publisher","first-page":"eaat6420","DOI":"10.1126\/scitranslmed.aat6420","volume":"10","author":"JL Garrido","year":"2018","unstructured":"Garrido, J. L. et al. Two recombinant human monoclonal antibodies that protect against lethal Andes hantavirus infection in vivo. Sci. Transl. Med. 10, eaat6420 (2018).","journal-title":"Sci. Transl. Med."},{"key":"70285_CR44","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abl5399","volume":"14","author":"E Mittler","year":"2022","unstructured":"Mittler, E. et al. Human antibody recognizing a quaternary epitope in the Puumala virus glycoprotein provides broad protection against orthohantaviruses. Sci. Transl. Med. 14, eabl5399 (2022).","journal-title":"Sci. Transl. Med."},{"key":"70285_CR45","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.cell.2022.02.023","volume":"185","author":"JC Milligan","year":"2022","unstructured":"Milligan, J. C. et al. Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses. Cell 185, 995\u20131007.e1018 (2022).","journal-title":"Cell"},{"key":"70285_CR46","doi-asserted-by":"publisher","first-page":"e1006198","DOI":"10.1371\/journal.ppat.1006198","volume":"13","author":"H Tian","year":"2017","unstructured":"Tian, H. et al. Anthropogenically driven environmental changes shift the ecological dynamics of hemorrhagic fever with renal syndrome. PLoS Pathog. 13, e1006198 (2017).","journal-title":"PLoS Pathog."},{"key":"70285_CR47","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","volume":"89","author":"HW Kim","year":"1969","unstructured":"Kim, H. W. et al. Respiratory syncytial virus disease in infants despite prior administration of an antigenic inactivated vaccine. Am. J. Epidemiol. 89, 422\u2013434 (1969).","journal-title":"Am. J. Epidemiol."},{"key":"70285_CR48","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1128\/jvi.57.3.721-728.1986","volume":"57","author":"GA Prince","year":"1986","unstructured":"Prince, G. A. et al. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. J. Virol. 57, 721\u2013728 (1986).","journal-title":"J. Virol."},{"key":"70285_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9143","volume":"6","author":"A Krarup","year":"2015","unstructured":"Krarup, A. et al. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat. Commun. 6, 8143 (2015).","journal-title":"Nat. Commun."},{"key":"70285_CR50","doi-asserted-by":"publisher","first-page":"12265","DOI":"10.1073\/pnas.1811980115","volume":"115","author":"GBE Stewart-Jones","year":"2018","unstructured":"Stewart-Jones, G. B. E. et al. Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1-4. Proc. Natl. Acad. Sci. USA 115, 12265\u201312270 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"70285_CR51","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1126\/science.abd0826","volume":"369","author":"CL Hsieh","year":"2020","unstructured":"Hsieh, C. L. et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science 369, 1501\u20131505 (2020).","journal-title":"Science"},{"key":"70285_CR52","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263 (2020).","journal-title":"Science"},{"key":"70285_CR53","doi-asserted-by":"publisher","first-page":"5339","DOI":"10.1038\/s41596-021-00623-0","volume":"16","author":"JM Schaub","year":"2021","unstructured":"Schaub, J. M. et al. Expression and characterization of SARS-CoV-2 spike proteins. Nat. Protoc. 16, 5339\u20135356 (2021).","journal-title":"Nat. Protoc."},{"key":"70285_CR54","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/bs.aivir.2017.02.002","volume":"98","author":"P Guardado-Calvo","year":"2017","unstructured":"Guardado-Calvo, P. & Rey, F. A. The Envelope proteins of the bunyavirales. Adv. virus Res. 98, 83\u2013118 (2017).","journal-title":"Adv. virus Res."},{"key":"70285_CR55","doi-asserted-by":"publisher","first-page":"4108","DOI":"10.1016\/j.vaccine.2021.05.098","volume":"39","author":"A Dey","year":"2021","unstructured":"Dey, A. et al. Immunogenic potential of DNA vaccine candidate, ZyCoV-D, against SARS-CoV-2 in animal models. Vaccine 39, 4108\u20134116 (2021).","journal-title":"Vaccine"},{"key":"70285_CR56","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1089\/10430340152528129","volume":"12","author":"SA Calarota","year":"2001","unstructured":"Calarota, S. A., Kjerrstr\u00f6m, A., Islam, K. B. & Wahren, B. Gene combination raises broad human immunodeficiency virus-specific cytotoxicity. Hum. Gene Ther. 12, 1623\u20131637 (2001).","journal-title":"Hum. Gene Ther."},{"key":"70285_CR57","first-page":"2782","volume":"8","author":"RM Conry","year":"2002","unstructured":"Conry, R. M. et al. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin. Cancer Res. 8, 2782\u20132787 (2002).","journal-title":"Clin. Cancer Res."},{"key":"70285_CR58","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/cncr.11462","volume":"98","author":"ST Tagawa","year":"2003","unstructured":"Tagawa, S. T. et al. Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma. Cancer 98, 144\u2013154 (2003).","journal-title":"Cancer"},{"key":"70285_CR59","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3390\/vaccines8030377","volume":"8","author":"J Hooper","year":"2020","unstructured":"Hooper, J. et al. A phase 2a randomized, double-blind, dose-optimizing study to evaluate the immunogenicity and safety of a bivalent DNA vaccine for hemorrhagic fever with renal syndrome delivered by intramuscular electroporation. Vaccines 8, 377 (2020).","journal-title":"Vaccines"},{"key":"70285_CR60","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.antiviral.2016.12.001","volume":"138","author":"DB Jiang","year":"2017","unstructured":"Jiang, D. B. et al. Recombinant DNA vaccine of Hantavirus Gn and LAMP1 induced long-term immune protection in mice. Antivir. Res. 138, 32\u201339 (2017).","journal-title":"Antivir. Res."},{"key":"70285_CR61","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","volume":"54","author":"MG Alameh","year":"2021","unstructured":"Alameh, M. G. et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity 54, 2877\u20132892.e2877 (2021).","journal-title":"Immunity"},{"key":"70285_CR62","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/s41565-023-01404-4","volume":"18","author":"X Han","year":"2023","unstructured":"Han, X. et al. Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines. Nat. Nanotechnol. 18, 1105\u20131114 (2023).","journal-title":"Nat. Nanotechnol."},{"key":"70285_CR63","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.aac4919","volume":"349","author":"AD Gitlin","year":"2015","unstructured":"Gitlin, A. D. et al. HUMORAL IMMUNITY. T cells help controls the speed of the cell cycle in germinal center B cells. Sci. (N. Y., NY) 349, 643\u2013646 (2015).","journal-title":"Sci. (N. Y., NY)"},{"key":"70285_CR64","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1038\/s41590-023-01597-9","volume":"24","author":"JF Brooks","year":"2023","unstructured":"Brooks, J. F. et al. Molecular basis for potent B cell responses to antigen displayed on particles of viral size. Nat. Immunol. 24, 1762\u20131777 (2023).","journal-title":"Nat. Immunol."},{"key":"70285_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00991-0","volume":"9","author":"J Zhang","year":"2024","unstructured":"Zhang, J. et al. A comprehensive investigation of Glycoprotein-based nucleic acid vaccines for Hantaan Virus. NPJ Vaccines 9, 196 (2024).","journal-title":"NPJ Vaccines"},{"key":"70285_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-024-02613-6","volume":"22","author":"J Wei","year":"2025","unstructured":"Wei, J. et al. Standardization, validation, and comparative evaluation of a convenient surrogate recombinant vesicular stomatitis virus plaque reduction test for quantification of Hantaan orthohantavirus (HTNV) neutralizing antibodies. Virol. J. 22, 31 (2025).","journal-title":"Virol. J."},{"key":"70285_CR67","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/BF01321121","volume":"122","author":"JS Yao","year":"1992","unstructured":"Yao, J. S. et al. Antibody-dependent enhancement of hantavirus infection in macrophage cell lines. Arch. Virol. 122, 107\u2013118 (1992).","journal-title":"Arch. Virol."},{"key":"70285_CR68","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.bbrc.2020.04.088","volume":"527","author":"M Yao","year":"2020","unstructured":"Yao, M. et al. N(6)-methyladenosine modifications enhance enterovirus 71 ORF translation through METTL3 cytoplasmic distribution. Biochem. Biophys. Res. Commun. 527, 297\u2013304 (2020).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"70285_CR69","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1080\/17425247.2019.1669558","volume":"16","author":"LM Ickenstein","year":"2019","unstructured":"Ickenstein, L. M. & Garidel, P. Lipid-based nanoparticle formulations for small molecules and RNA drugs. Expert Opin. drug Deliv. 16, 1205\u20131226 (2019).","journal-title":"Expert Opin. drug Deliv."},{"key":"70285_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00814-2","volume":"9","author":"H Zhang","year":"2024","unstructured":"Zhang, H. et al. Single-dose recombinant VSV-based vaccine elicits robust and durable neutralizing antibody against Hantaan virus. NPJ Vaccines 9, 28 (2024).","journal-title":"NPJ Vaccines"},{"key":"70285_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1121163","volume":"13","author":"YL Hu","year":"2023","unstructured":"Hu, Y. L. et al. Construction and evaluation of a DNA vaccine encoding the Crimean Congo hemorrhagic fever virus nucleocapsid protein, glycoprotein N-terminal and C-terminal fused with LAMP1. Front. Cell. Infect. Microbiol. 13, 1121163 (2023).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"70285_CR72","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.3389\/fphar.2019.01203","volume":"10","author":"C Ye","year":"2019","unstructured":"Ye, C. et al. An improved enzyme-linked focus formation assay revealed baloxavir acid as a potential antiviral therapeutic against hantavirus infection. Front. Pharmacol. 10, 1203 (2019).","journal-title":"Front. Pharmacol."},{"key":"70285_CR73","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jviromet.2009.09.006","volume":"163","author":"SR Vaidya","year":"2010","unstructured":"Vaidya, S. R. et al. Development of a focus reduction neutralization test (FRNT) for the detection of mumps virus neutralizing antibodies. J. Virol. Methods 163, 153\u2013156 (2010).","journal-title":"J. Virol. Methods"},{"key":"70285_CR74","doi-asserted-by":"crossref","unstructured":"Yang, Q.\u00a0et al. Establishment and optimization of a rapid and convenient viral RNA transcript copy reduction neutralization test (VcRNT) for quantification of Hantaan orthohantavirus (HTNV) neutralizing antibodies. Virology 608, 110542 (2025).","DOI":"10.1016\/j.virol.2025.110542"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70285-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70285-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70285-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:03:27Z","timestamp":1777633407000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70285-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["70285"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-70285-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,14]]},"assertion":[{"value":"9 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Authors W.Y., F.L.Z., Y.D., L.F.C., H.Z., L.Z., H.L., and Z.K.X. are inventors on a provisional patent application filed in China (Application No. CN202310156260.7) related to the prefusion-stabilized HTNV glycoprotein vaccine design described in this study. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3972"}}